XML 60 R41.htm IDEA: XBRL DOCUMENT v2.4.0.8
CO-DEVELOPMENT AND LICENSE AGREEMENT - Additional Information (Details) (USD $)
1 Months Ended 0 Months Ended 0 Months Ended 1 Months Ended 0 Months Ended
Jul. 31, 2014
Sep. 30, 2014
Jul. 07, 2014
Common Stock Purchase Agreement
Feb. 12, 2014
Common Stock Purchase Agreement
Maximum
Sep. 30, 2014
MIN-202
Feb. 12, 2014
MIN-202
Co-development and License Agreement
Jul. 31, 2014
MIN-202
Co-development and License Agreement
Feb. 12, 2014
MIN-202
Co-development and License Agreement
Period one
Maximum
Feb. 12, 2014
MIN-202
Co-development and License Agreement
Period two
Maximum
Co-development and license agreement                  
Payment of initial upfront license fee $ 22,000,000           $ 22,000,000    
Percentage of development costs related to joint development of products           40.00%      
Share of aggregate development cost following completion of Phase Ib clinical trials and animal toxicology studies               5,000,000 24,000,000
Period within which agreement is terminated related to Phase Ib clinical trials milestone           45 days      
Termination fee related to Phase Ib clinical trial milestone           3,000,000      
Accrued collaborative expenses   1,386,493     1,386,493        
Common stock agreed to be issued (in shares)       26,000,000          
Common stock issued (in shares)     3,284,353            
Net proceeds from issuance of common stock     $ 19,700,000